CTI Adds Three Leaders in Blood Cancer Research and Development to SAB
Complete the form below to unlock access to ALL audio articles.
Cell Therapeutics, Inc. has announced the addition of three leaders in the research and development of new treatments for blood-related cancers to CTI's recently formed Scientific Advisory Board (SAB): Alan List, M.D., President and CEO of Moffitt Cancer Center; Ross Levine, M.D., Associate Attending Physician at Memorial Sloan-Kettering Cancer Center; and Brian Druker, M.D., Director of the Knight Cancer Institute at Oregon Health & Science University (OHSU).
The SAB will advise on the development of CTI's oncology programs and evaluate new opportunities in the treatment of blood-related cancers.
CTI's SAB is chaired by Daniel Von Hoff, M.D., F.A.C.P., Physician in Chief and Director of Translational Research at the Translational Genomics Research Institute (TGen), Chief Scientific Officer for US Oncology and for Scottsdale Healthcare's Clinical Research Institute.
"We are pleased to add this group's insight as distinguished leaders in the research and development of new treatments for blood-related cancers to our SAB," stated James A. Bianco, M.D., President and CEO of CTI. "Under Dan's leadership, the SAB will play an important role in the strategic development of our oncology portfolio and clinical trial design, review in-licensing and out-licensing opportunities, and assist in the use of translational and personalized approaches to therapeutic targets."
Brief biographies of the three new members are below:
Brian J. Druker, M.D.
Dr. Druker is the Director of the Knight Cancer Institute at Oregon Health & Science University (OHSU), JELD-WEN Chair of Leukemia Research at OHSU, and an Investigator of the Howard Hughes Medical Institute.
Dr. Druker's work was instrumental in the development of GLEEVEC® (imatinib), a drug that targets the molecular defect in chronic myeloid leukemia (CML). His role in the development of imatinib and its application in the clinic have resulted in numerous awards for Dr. Druker, including the John J. Kenney Award from The Leukemia and Lymphoma Society, the AACR-Richard and Hinda Rosenthal Award, the Warren Alpert Prize from Harvard Medical School, the American Society of Hematology's Dameshek Prize, the American Cancer Society's Medal of Honor, the David A. Karnofsky Award from the American Society of Clinical Oncology, the Robert-Koch Award, and most recently, the Lasker-DeBakey Clinical Medical Research Award from The Albert and Mary Lasker Foundation. He has been elected to the Institute of Medicine of the National Academies, the American Association of Physicians, the National Academy of Sciences and the American Academy of Arts and Sciences.
Ross L. Levine, M.D.
Dr. Levine is an Associate Attending Physician at Memorial Sloan-Kettering Cancer Center in the Human Oncology and Pathogenesis Program and Leukemia Service and is an Associate Professor of Medicine at Weill Cornell Medical College. He is a physician scientist with expertise in the molecular genetics of myeloid malignancies, including myeloproliferative neoplasms (MPN) and acute myeloid leukemia (AML).
The focus of the Levine laboratory is to improve the understanding of the genetic basis of myeloid malignancies, with a specific focus on the role of oncogenic disease alleles in the pathogenesis of MPN and AML. He has been involved in the discovery and characterization of disease alleles in MPN and AML patients, including the identification of JAK2 and MPL mutations in MPN patients.
Dr. Levine serves on the editorial board of Blood, Haematologica (Associate Editor) and Clinical Cancer Research and is a member of the International Working Group for Myelofibrosis. He has earned a Young Investigator Award from the American Society of Clinical Oncology, a Fellow Scholar Award from the American Society of Hematology and a Clinical Scientist Development Award from the Doris Duke Charitable Foundation. He is a Scholar of the Leukemia and Lymphoma Society. He serves on the Medical and Scientific Advisory Board of the Leukemia and Lymphoma Society, and is the chair of the Committee on Epigenetics and Genomics of the American Society of Hematology.
Alan F. List, M.D.
Dr. List is the President and CEO of Moffitt Cancer Center. He is a senior member in the Department of Malignant Hematology and the Experimental Therapeutics Program. In addition, Dr. List is a professor of internal medicine and oncology at the University of South Florida College of Medicine.
Dr. List's research interests include novel therapeutic agents to treat acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). He and his research team are nationally recognized for their contributions to understanding the biology of AML and MDS in order to develop more effective treatment strategies.
The former leader of Moffitt's Malignant Hematology Program, Dr. List was the lead investigator for a study that showed important clinical results for REVLIMID® (lenalidomide), which has received fast-track designation from the U.S. Food and Drug Administration to treat MDS and multiple myeloma.
